Formulation and ccd-based optimization of clonidine HCL-loaded microemulsion nanoparticles for enhanced intranasal delivery in anxiety disorders

IN605547BActive Publication Date: 2026-10-09DR SHAILESH SHARMA +5
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IN202511071039
Authority / Receiving Office
IN · IN
Patent Type
Patents
Current Assignee / Owner
Filing Date
2025-07-25
Publication Date
2026-10-09
Estimated Expiration
2045-07-25

AI Technical Summary

Technical Problem

Intranasal drug delivery systems face challenges such as mucociliary clearance, enzymatic degradation, and limited drug solubility and permeability, which hinder the effectiveness of Clonidine HCL delivery, leading to suboptimal therapeutic outcomes for conditions like anxiety disorders.

Method used

A microemulsion-based nanoparticulate delivery system comprising an oil phase, surfactant/co-surfactant mixture, and aqueous phase is developed, optimized to have a particle size of approximately 250 to 300 nm, with a zeta-potential of -4.96 mV, enhancing solubility, stability, and protecting Clonidine HCL from enzymatic degradation, and exhibiting a biphasic drug release pattern.

Benefits of technology

The system provides improved solubility, stability, and bioavailability of Clonidine HCL, achieving prolonged drug release and enhanced brain targeting, thereby improving therapeutic efficacy and patient compliance.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A microemulsion-based nanoparticulate delivery system has been developed for the intranasal delivery of Clonidine HCL. This system includes a microemulsion with an oil phase of isopropyl myristate, a surfactant / co-surfactant mixture of Tween 80 and PEG 400, and an aqueous phase containing distilled water with dissolved Clonidine HCL. The formulation is optimized to achieve a particle size of approximately 250 to 300 nm, a polydispersity index of about 0.274, and a zeta-potential of approximately -4.96 mV. It demonstrates a high drug entrapment efficiency of around 65.3% and exhibits a biphasic release pattern with an initial burst followed by a slow-release phase lasting 8 hours. The drug release kinetics align with the Korsmeyer–Peppas model, indicating anomalous transport. Stability studies suggest the formulation is robust for long-term storage, enhancing solubility and membrane permeability while protecting against enzymatic degradation. Figure 01.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present disclosure relates to a microemulsion-based nanoparticulate delivery system,and more particularly, to a delivery system for intranasal administration of Clonidine HCL.BACKGROUND

[0002] Intranasal drug delivery systems have gained significant attention in recent years due to theirpotential to provide rapid and efficient drug absorption directly into the systemic circulation,bypassing the first-pass metabolism associated with oral administration. This route is particularlyadvantageous for drugs that require quick onset of action or those that are poorly absorbed throughthe gastrointestinal tract. The nasal cavity offers a large surface area, high vascularization, and arelatively permeable epithelial membrane, making it an ideal site for drug delivery. However,challenges such as mucociliary clearance, enzymatic degradation, and limited drug solubility andpermeability can hinder the effectiveness of intranasal formulations.

[0003] Clonidine HCL is a medication commonly used for the treatment of hypertension and certainanxiety disorders. Its therapeutic efficacy can be significantly enhanced through improved deliverymethods that ensure consistent and controlled release. Traditional delivery methods may not providethe desired pharmacokinetic profile, leading to suboptimal therapeutic outcomes. Therefore, there isa growing need for innovative delivery systems that can enhance the solubility, stability, andbioavailability of Clonidine HCL, while also providing a controlled release to maintain therapeuticdrug levels over an extended period. Addressing these challenges can lead to improved patientcompliance and better management of conditions such as anxiety disorders.

[0004] Waqar et al. (2025) carried out a review article on the therapeutic efficacy and drug deliveryapplications supported by selenium nanoparticles (SeNPs), which heralded significant developmentsin nanomedicine. Physicochemical Properties slightly different from bulk selenium and othernanoparticles, SeNPs (1-100 nm). These are ideal for biomedical applications and thebiocompatibility, low systemic toxicity and selective cell cytotoxicity of these contrast agents. Allareas in Waqar et al. (2025) Are there Strong ways to support these improvements withoutcompromising bioavailability of all already said therapeutic agents like water-soluble molecules,peptides, proteins vaccines and other biologics SeNPs. Most importantly, surface ligand conjugationenables site-selective drug delivery by SeNPs in theory increasing efficacies and minimize off-targeteffects. The review also reviewed several routes to synthesis, physical, chemical and biological routeswith advantages in terms of stability plus large-scale manufacturing. In addition to cancer, SeNPs withconsiderable therapeutic potentials in neurodegenerative diseases (Alzheimer's disease) and chronicinflammatory conditions e.g., diabetic nephropathy have also been reported. In agreement with theantimicrobial / anti-inflammatory context, immunomodulatory in nature effects elicited by theseobserved immune responses and macrophage polarization regulation potentials for their cell PAMPtargets continue besides their relevance. The innovations such as mannosylated SeNPs, among manyother clearly highlighted by Waqar (2025) integration of targeting strategies developed intonanocarrier systems. Combined, this review marks SeNPs as a leading and broad-based option withinthe future paradigms for drug delivery and biotherapy.

[0005] Hamidi et al. (2025) Hamidi review about the in vitro systems and techniques currently usedwithin nano systems for intranasal drug delivery in psychiatric diseases, focusing on the hurdles ofBBB (blood-brain barrier) and common routes of administration. Given this, the intranasal (nose tobrain) route is stressed as an important, non-invasive method for drug delivery that avoids the BBBdirectly targeting the brain. The available nanocarriers such as polymeric nanoparticles, liposomesand nano emulsions have been reviewed in detail by authors to enhance the brain delivery of anticancerdrug delivery via intranasal route. The narrative review highlights the potential of intranasal deliveryfor mood / anxiety disorders and schizophrenia. It further elucidates use of next generation nanocarrierformulations such as nanoparticles, in situ gel, nano emulsion, hydrogels and liposomes for improvingthe therapeutic efficacy and delivery in psychiatric diseases.

[0006] Papola et al. (2024) In a thorough meta-analysis, researchers have looked back at digitalmental health interventions for anxiety disorders and reported that immersive technologies especiallyvirtual reality (VR) are much more effective than interaction less approaches. We found that VRtreatments, especially exposure therapy for phobias and social anxiety disorders had large effect sizesof approximately 1.03-1.18 (Cohen's d), representing a substantial alleviation in anxiety. Mobile appsand web-based cognitive behavioral therapy (CBT) interventions, though still helpful, showed smallereffect sizes of around 0.55-0.85 when delivered via CBT platforms. These data suggest that itsimmersive character allows VR to deepen the emotional experience and presence which would explainthe better therapeutic outcome. Dropout rates were also lower in VR (6-8%) compared to those usingmobile and web-based tools (10-15%) making it clear (but not surprising) what one prefers as animmersive environment. Johnson et al., in general Terms seem to emphasize the potential of digitalinterventions-particularly immersive VR as widely available, scalable and effective treatments forpeople with anxiety disorders.

[0007] Kinge et al. (2024) a Microemulsion, is a clear or nearly clear, thermodynamically stable, andquasi-homogeneous system consisting of two immiscible liquids and stabilized by a surfactant or asurfactants mixture. Microemulsions have been used as carriers for pharmaceutical drug deliverybecause of their particular characteristics, including its optical transparency, high thermodynamicstability and simplicity of preparation. Microemulsions have shown several advantages overtraditional topical and transdermal delivery systems, as a result of their physicochemical properties.In addition, microemulsion dispersions are potential controlled-release drug delivery systems andeffective vehicles for oral, topical, and parenteral applications. Apart from pharmaceuticals,microemulsions have considerable promise in cosmetics and household products. This review is abrief description of the preparation, characterization and various applications of microemulsions.

[0008] Parmar et al. (2024) define microemulsions as complex liquid systems of great technologicalinterest, particularly in the pharmaceutical field. Functional silicate-based DDS. These DDS areusually combined form DDS using other substances such as drugs, polymers and nanoparticles, whichmakes them more complicated. Microemulsions are clear, thermodynamically stable, isotropicsystems containing two immiscible liquids such as oil and water, and a surfactant along with a cosurfactant.Due to their structure and function, they are highly desirable as drug carriers that can hosta wide range of drug moieties. A complete knowledge and control of their preparation and behaviorcan be achieved by using several complementary analytical methods. Due to their ability to improvedrug solubility, stability, and bioavailability, microemulsions have attracted increasing interest as apromising and emergent vehicle for pharmaceutical purposes.

[0009] Patel et al. (2024) undertook a systematic approach for the development and assessment of amicroemulsion-based transdermal delivery system for anti-inflammatory drugs, which aimed toovercome limitations of conventional topical or oral drug delivery. The model anti-inflammatorydrug used in this study is potentially limited in effectiveness because of its low skin permeation andrapid systemic clearance. Using oils, surfactant (e.g., Tween 80), and co-surfactant (e.g., ethanol orpropylene glycol), the formulation was optimized using pseudo-ternary phase diagrams to locatethermodynamically stable, isotropic, and transparent microemulsion zones. The microemulsionsformed had nano droplet size (approximately <100 nm), low viscosity, and large surface area; suchwould allow for effective transdermal administration. In vitro permeation studies using Franzdiffusion cells and excised rat skin showed a statistically (P < 0.05) higher drug permeation ascompared to conventional cream, due to the disruption of the stratum corneum by surfactants andsubmicron droplet size. The stability testing reported the physicochemical stability of the systemduring the storage under different conditions, and the skin irritation studies revealed that erythema oredema on rabbit skin were not apparent, suggesting good dermatological compatibility. Overall, Patelet al. novel methyl ester derivatives, desirable to treat psoriasis, could constitute a safe, efficient andpatient compliance tactic as for non-invasive and long transcutaneous delivery of the antiinflammatorydrugs, with a promising commercial translation.

[0010] Zha et al. (2022) focus on the problems of intravenous nanomaterials for neurologicaldisorders that are largely blood-brain-barrier (BBB) restricted. This article highlights that theintranasal delivery of nanoparticles (NPs) provides a non-invasive way for direct passage intoolfactory and trigeminal nerves, sidestepping BBB and thus region-specific targeting of brain areas.It is a route that allows for efficient drug and gene delivery to treat CNS diseases. This review willcritically examine the current strategies for intranasal delivery of the functionalized NPs withrespective mechanisms of their brain penetrations and accelerate developments of thesenanocomposites for multimodal bioimaging, diagnostics & therapeutics. The authors summarize herethe challenges and possible future directions in the area of intranasal delivery of nanomaterial.

[0011] Jones et al. (2021) A large-scale meta-analysis of cognitive-behavioural therapy (CBT) in themanagement of various anxiety disorders such as generalized anxiety disorder, panic disorder andsocial anxiety disorder This meta-analysis incorporated clinical trial from many studies, mapping outa strong picture of the positive contribution CBT makes as an intervention for various anxietysubtypes. Jones et al Results (2021) further confirmed that CBT is one of the leading treatments foranxiety disorders with reliable and significant effect sizes reported across multiple anxiety disorders.This is consistent with the use of CBT being a first-line therapy in clinical practice. The studyunderscored some major aspects of CBT that makes it so effective. One of the pillars of CBT iscognitive restructuring, which pulls out irrational or harmful thought patterns as processes to tryreplace with the other end of anxiety.

[0012] Tabosa do Egito et al. (2021) point out the difficulties of poorly soluble API in drugformulations, which may lead to the delayed pharmaceutical screening and production. Novel drugdelivery strategies are urgently required to minimize the use of solubility enhancing excipients andto increase the bioavailability. Microemulsions are being recognized as promising nanotechnologicalplatforms for the safe delivery of poorly soluble drugs with improved biopharmaceutical profiles andpharmacokinetics. The state-of-the art in the field of microemulsion systems are detailed in thisextensive review, which embraces their history, design rules, production, and characterizationtechniques. They also discuss regulatory considerations regarding stability and toxicity assessments.Overall, the review emphasizes the great prospects for microemulsion systems as versatile drugdelivery vehicles for various administration routes and therapeutic use.

[0013] Lashkari et al. (2021) systematic review aimed to study the use of nanoparticles (NPs) andnanoscale formulations of drug on the management of microbial infections in central nervous system(CNS), a major public health problem charactered by high morbidity and mortality rates as treatmentadvance into CNS. The limitations of in vivo drug delivery across the blood-brain barrier (BBB)-asthe authors brought attention to - are a problem with traditional antibiotics. There is therefore a needfor nanotechnology that could make possible to accomplish newer and more effective drug deliveryacross the BBB. This meta-analysis of drug-laden nanoparticles in a broad search through severaldatabases, the review concluded that upon intranasal administration, they hold high safety and tenfoldincreased efficacy as compared to free drugs mainly against CNS bacterial infection. Preclinical datalent credence to the premise that NP-based therapies may translate into improved treatment outcomes(Lashkari et al. (2021) urgently called for functional clinical trials to support the safety and efficacyof these nano formulations in human patients.SUMMARY

[0014] The microemulsion-based nanoparticulate delivery system may be used for intranasaldelivery of Clonidine HCL. The system can include a microemulsion with an oil phase, asurfactant / co-surfactant mixture, and an aqueous phase. The oil phase may contain isopropylmyristate, the surfactant / co-surfactant mixture can include Tween 80 and PEG 400, and the aqueousphase may have distilled water with dissolved Clonidine HCL.

[0015] The delivery system can be optimized to have a particle size of approximately 250 to 300nm. The formulation may also possess a polydispersity index indicating good size distribution,approximately 0.274.

[0016] The optimized formulation may have a zeta-potential within an acceptable range ofapproximately -4.96 mV. Additionally, the system can achieve a high entrapment efficiency of thedrug, approximately 65.3%. The optimized formulation (O1) possesses good physicochemicalproperties including nasal mucosa compatible pH (6.7 ± 0.2), desirable viscosity for retention (65.0 ±3.0 cPs), drug content (99.04% w / w) high entrapment efficiency (65.3 ± 0.3%) and nanosizedparticles (~281.9 nm). The system also exhibits a prolonged in vitro drug release for up to 8 hdominating with non-Fickian (anomalous) diffusion mechanism. A zeta potential measurementsprovided evidence indicating colloidal stability, and SEM microphotography also showed that NPswere spherical and uniform in size.

[0017] In vitro release studies may show a biphasic release pattern with an initial burst and slow15release phases, allowing for slow release over 8 hours. The drug release kinetics can be best describedby the Korsmeyer-Peppas model, demonstrating anomalous (non-Fickian) transport controlled bydiffusion and polymer matrix relaxation.

[0018] The invention includes a long-term physical and chemical stability for the drug under stressof accelerated ICH conditions (40±2°C / 75±5% RH), as observed by drug content, release profile,and the remaining critical parameters without much change at long-term storage. This intranasalnanosystem based on microemulsion provides improved brain targeting through the olfactorypathway, increased bioavailability, lower systemic exposure, as well as enriched patient compliance.It overcomes the drawbacks of traditional oral / systemic administration of Clonidine Hydrochlorideand flags the formulation as a promising therapeutic system for efficient and non-invasivemanagement of anxiety.

[0019] The system can increase the solubility and maintain the solubilized state of Clonidine HCL.It may also act as a promoter for membrane permeability of Clonidine HCL and protect ClonidineHCL from enzymatic degradation.BRIEF DESCRPTION OF DRAWINGSFIG. 1 shows In vitro drug release profile of optimized formulation, O1.FIG. 2 shows the % cumulative drug released over time, comparing 0 days and 4 weeks, indicating astable biphasic release pattern evaluated under accelerated stability conditions (40 °C ± 2 °C / 75%RH ± 5%)DETAILED DESCRIPTION

[0020] The disclosure provides a microemulsion-based nanoparticulate delivery system designedfor the intranasal delivery of Clonidine HCL. This system may include a microemulsion composed ofan oil phase, a surfactant / co-surfactant mixture, and an aqueous phase. The oil phase may consist ofisopropyl myristate, while the surfactant / co-surfactant mixture may include Tween 80 and PEG 400.The aqueous phase may contain distilled water with dissolved Clonidine HCL. The system canenhance drug delivery by increasing the solubility and maintaining the solubilized state of ClonidineHCL, acting as a promoter for membrane permeability, and protecting the drug from enzymaticdegradation. The optimized formulation may possess favourable physicochemical characteristics fornasal delivery, such as a particle size of approximately 250 to 300 nm, a polydispersity indexindicating good size distribution, and a zeta-potential within an acceptable range. The formulationmay also demonstrate a high entrapment efficiency of the drug and a biphasic release pattern withinitial burst and slow-release phases, affording slow release for 8 hours. The drug release kinetics maybe best described by the Korsmeyer-Peppas model, demonstrating anomalous transport controlled bydiffusion and polymer matrix relaxation. An accelerated ICH stability program may indicate nosignificant variability in formulation characteristics, suggesting robustness and suitability for longtermstorage.

[0021] FIG. 1 illustrates the cumulative drug release profile of the microemulsion-basednanoparticulate delivery system for Clonidine HCL over a period of 480 minutes. The graph is a visualrepresentation of the drug release dynamics, which is important for understanding the therapeuticefficacy of the delivery system. The Y-axis represents the percentage of cumulative drug released,while the X-axis shows the time intervals in minutes. This graph demonstrates a biphasic releasepattern. The initial burst release is evident in the early time intervals, where a significant percentageof the drug is released rapidly. This is followed by a slow-release phase, where the rate of drug releasedecreases, allowing for sustained therapeutic levels over an extended period.

[0022] The biphasic release pattern is beneficial for maintaining therapeutic levels of ClonidineHCL, as it ensures an initial rapid onset of action followed by a prolonged release to maintain efficacy.This release profile is particularly advantageous for conditions requiring steady drug levels, such asanxiety disorders. The initial burst may help achieve the desired therapeutic effect quickly, while the slow-release phase ensures that the drug remains effective over time without frequent dosing. The graph indicates that by 480 minutes, a substantial percentage of the drug has been released, aligning with the goal of providing a controlled release system.

[0023] The microemulsion-based nanoparticulate delivery system utilizes isopropyl myristate as the oil phase, Tween 80 and PEG 400 as the surfactant / co-surfactant mixture, and distilled water with dissolved Clonidine HCL as the aqueous phase. This formulation is optimized to achieve a particle size of approximately 250 to 300 nm, a polydispersity index of 0.274, and a zeta-potential of -4.96 mV, ensuring good stability and drug entrapment efficiency. The system's ability to enhance solubility, maintain the solubilized state, and protect the drug from enzymatic degradation is important for its effectiveness. The release kinetics, best described by the Korsmeyer-Peppas model, indicate anomalous transport controlled by diffusion and polymer matrix relaxation, further supporting the system's design for controlled drug delivery. The stability of the formulation over time, as indicated by consistent release patterns, suggests its robustness for long-term storage and use.

[0024] FIG. 2 presents a graph illustrating the percentage of cumulative drug release over time for a microemulsion-based nanoparticulate delivery system of Clonidine HCL. The Y-axis represents the percentage of cumulative drug released, while the X-axis indicates time intervals in minutes, spanning up to 480 minutes. The graph features two lines: a blue line representing the release pattern at 0 days and an orange line for 4th week. Both lines exhibit a biphasic release pattern, characterized by an initial burst followed by a slow-release phase. This pattern emphasizes maintaining therapeutic levels over an extended period.

[0025] The graph demonstrates the stability and robustness of the formulation over 1 month, as indicated by the consistent drug release pattern between the two time points. This stability is important for long-term storage and use, ensuring that the formulation maintains its efficacy and release characteristics over time. The biphasic release pattern is beneficial for providing a controlled release, which is advantageous for maintaining therapeutic levels in the treatment of conditions such as anxiety disorders. The initial burst allows for rapid onset of action, while the subsequent slow-release phase ensures sustained drug delivery, reducing the frequency of administration and enhancing patient compliance.

[0026] The microemulsion-based system comprises an oil phase of isopropyl myristate, a surfactant / co-surfactant mixture of Tween 80 and PEG 400, and an aqueous phase of distilled water with dissolved Clonidine HCL. This composition enhances the solubility and maintains the solubilized state of Clonidine HCL, acting as a promoter for membrane permeability and protecting the drug from enzymatic degradation. The optimized formulation possesses favourable physicochemical characteristics, including a particle size of approximately 281.9 nm, a polydispersity index of 0.274, a zeta-potential of -4.96 mV, and a high entrapment efficiency of approximately 65.3%. These characteristics contribute to the system's effectiveness in delivering Clonidine HCL intranasally, providing a controlled and sustained release that is important for therapeutic efficacy.

[0027] The optimization and development of Clonidine Hydrochloride microemulsion based nanoparticles for intranasal delivery for improved treatment of anxiety. It was prepared by a method of microemulsion synthesis of nanoparticles and this method involves dissolving distilled water (aqueous phase) drug Clonidine Hydrochloride in isopropyl myristate (IPM) as an oil phase. The surfactant and co-surfactant, tween 80 and polyethylene glycol 400 (PEG 400) were mixed in the ratio of 2:1 (Smix system). This ratio was selected as optimal, according to the construction of pseudo ternary phase diagrams, since it exhibited a larger area of microemulsion forming region, suggesting improved emulsifying capability and formulation stability.

[0028] Microemulsion was prepared by adding the aqueous drug solution drop wise to the combination of oil-Smix mixture with continuous magnetic stir for 5-10 minutes, followed by probe sonication for 10-15 minutes to get nanometric dispersion and uniformity. Optimization of the formulation was carried out by Central Composite Design (CCD) in order to investigate the effect of three independent variables, oil (X1), (Smix) ratio of Tween 80 and polyethylene glycol 400 (X1), and distilled water (X3) on critical process responses, such as pH (Y1), viscosity (Y2), and entrapment efficiency (Y3). Statistical analysis and AVOVA revealed high R2 values and significant F-values of the developed quadratic models, evidencing the suitability of the model. The optimized final formulation (coded O1) had pH of 6.7 ± 0.2, a viscosity of 65 ± 3 cPs, and the entrapment efficiency was 65.3 ± 0.3%, similar to the predicted values, which indicated the fairness of the optimization process.

[0029] In addition, particle size measurements showed a Z-average size of 281.9 nm with a PDI valueof 0.274, indicating monodisperse nanoparticle distribution suitable for intranasal administration. Thezeta potential -4.96 mV revealed a negative surface charge, which would keep the colloid in a wellstate too. SEM morphological analysis further proved that the particles were smooth-surfacedspheroids. The in-vitro release studies indicated retention of drug release for 480 min and Korsmeyer-Peppas kinetic model (R2 = 0.9781) demonstrated anomalous (non-Fickian) transport, therebyachieving prolonged therapeutic effect.

[0030] The invention provides a statistically optimized new method for intranasal microemulsionbased delivery of Clonidine HCl that overcomes the drawbacks associated with low CNS penetrationand systemic adverse effects associated with oral conventional dosage forms. This optimizednanosystem can lead to more efficient brain targeting, less frequency of dosing, and subsequentlybetter patient compliance, resulting it as a promising alternative for clinical therapy of anxietydisorders.EVALUATION OF THE OPTIMIZED FORMULATION (O1)

[0031] The optimized Clonidine HCl-loaded microemulsion-based nano-particulate formulation (O1)was characterized to ensure it appropriateness for nasal delivery. Key evaluations revealed pH(6.7±0.2) ensuring mucosal compatibility, viscosity (65±3 cPs) contributing to enhanced residencetime in nasal cavity, and high entrapment efficiency (65.3±0.3%) implying successful drug loading.The particle size was determined by dynamic light scattering and was identified to be nanosized, withan average diameter of 281.9nm and a PDI 0.274, indicating a homogeneous distribution. Zetapotential was -4.96mV, and the good colloidal stability. SEM images indicated the particle wasspheroidal in shape and had a smooth surface. Moreover, Drug content of the optimized formulation (O1)was 99.04% w / w, indicating high drug loading and negligible loss during processing of formulation. FTIRstudies indicated that there was no interaction between the drug and the excipients so as to maintainthe integrity of the formulation. In vitro drug release kinetics indicated a biphasic pattern with releaseover 480minutes and was consistent with Korsmeyer-Peppas model (R2=0.9781) for anomalous (non-Fickian) transport. Stability studies (40±2°C / 75±5% RH for 1 month) demonstrated little effect on thepH, viscosity, content uniformity, and release pattern indicating the formulation's physical andchemical integrity. Taken together with the results, the optimized microemulsion may serve as apromising candidate for efficient and long-term intranasal delivery of Clonidine HCl in anxiety therapy.Table 1: Composition of Clonidine Hydrochloride - loaded microemulsionTable 2: Predicted and Observed values of dependent variables for Optimized formulation, O1* Data has been expressed as Mean ± SD, n = 3Table 3: Percentage cumulative drug release vs Time intervals data of Optimized formulation, O1time intervals (min)* Data has been expressed as Mean ± SD, n = 3STABILITY EVALUATION OF OPTIMIZED FORMULATION (O1):

[0032] The optimized intranasal microemulsion formulation (O1) of Clonidine HCl was selected for accelerated stability study in accordance with ICH Q1A(R2) guidelines to check the physicochemical integrity and shelf-life. The formulation was kept in sealed containers protected from light for 4 weeks in an environmental chamber at 40 + 2°C and 75 + 5% RH. The developed formulation was analyzed at scheduled intervals starting from (0 days to 1, 2, 3, and 4) weeks for physicochemical parameters such as physical appearance, pH, viscosity, entrapment efficiency (%EE), and in vitro drug release. The formulation remained clear and transparent during the study and there was no separation of phase or turbidity indicating physical stability. pH remained within the mucosal tolerance range (6.6 ± 0.2 to 6.7 ± 0.8) and its viscosity was constant (65.0 ± 3.0 cPs), which suggests the stability of the formulation matrix. The entrapment efficiency was always higher than 65%, suggesting mild drug leakage and good retention inside the nanoparticle matrix. Comparative in vitro dissolution studies on day 0 and 4th week revealed there was no significant difference in the release kinetics with a model independent dissimilarity factor (f₁) of 1.75 and a similarity factor (f₂) of 91. 68, which are in acceptable regulatory range. The results indicate the stability of the formulation, which demonstrates that the developed Clonidine HCl-loaded microemulsion nano particle system is stable both chemically and functionally, upon accelerated storage conditions, and it can be used for long pharmaceutical utilization.Table 4: Stability data of Optimized Formulation, O1Accelerated conditions (40 °C ± 2 °C / 75 %RH ± 5 %RH)Table 5: In vitro drug release data of Optimized Formulation, O1 at Accelerated conditions (40 °C ± 2 °C / 75 %RH ± 5 %RH)% Cumulative drug released

Claims

1. A microemulsion-based nanoparticulate delivery system for intranasal delivery of Clonidine HCL, comprising: - a microemulsion comprising an oil phase, a surfactant / co-surfactant mixture, and an aqueous phase, characterized in that: - the oil phase comprises isopropyl myristate, - the surfactant / co-surfactant mixture comprises Tween 80 and PEG 400, and - the aqueous phase comprises distilled water with dissolved Clonidine HCL.

2. The microemulsion-based nanoparticulate delivery system according to claim 1, wherein the optimized formulation possesses a particle size of approximately 250 to 300 nm.

3. The microemulsion-based nanoparticulate delivery system according to claim 1, wherein the optimized formulation possesses a polydispersity index indicating good size distribution of approximately 0.274.

4. The microemulsion-based nanoparticulate delivery system according to claim 1, wherein the optimized formulation possesses a zeta-potential within an acceptable range of approximately -4.96 mV.

5. The microemulsion-based nanoparticulate delivery system according to claim 1, wherein the optimized formulation possesses a high entrapment efficiency of the drug of approximately 65.3%.

6. The microemulsion-based nanoparticulate delivery system according to claim 1, wherein in vitro release studies show a biphasic release pattern with an initial burst and slow-release phases, affording slow release for 8 hours.

7. The microemulsion-based nanoparticulate delivery system according to claim 6, wherein the drug release kinetics are best described by the Korsmeyer-Peppas model, demonstrating anomalous (non-Fickian) transport controlled by diffusion and polymer matrix relaxation.

8. The microemulsion-based nanoparticulate delivery system according to claim 1, wherein an accelerated ICH stability program indicates no significant variability in formulation attributes, suggesting that the formulation is robust and ideal for long-term storage.

9. The microemulsion-based nanoparticulate delivery system according to claim 1, wherein the system increases the solubility and maintains the solubilized state of Clonidine HCL.

10. The microemulsion-based nanoparticulate delivery system according to claim 1, wherein the system acts as a promoter for membrane permeability of Clonidine HCL.

11. The microemulsion-based nanoparticulate delivery system according to claim 1, wherein the system protects Clonidine HCL from enzymatic degradation.